This DNDi-supported project will streamline and accelerate use of new, child- friendly ART formulations. EGPAF will focus on the development of new tools for improved control of pediatric HIV and support increased uptake of solid lopinavir/ ritonavir, while preparing for introduction of dispersible dolutegravir formulations in Kenya, Tanzania* and Uganda**.
*Project closed in Tanzania in 2021
**Project closed in Uganda in 2020.